《中国糖尿病杂志》官方网站

20

您的位置:首页 > 中国糖尿病杂志 > 2012年 > 9期

Vaspin与肥胖及2型糖尿病相关性研究进展

来自:中国糖尿病资讯网  编辑:editor|点击数:|2012-10-17

  【摘要】 内脏脂肪特异性丝氨酸蛋白酶抑制剂(vaspin)是近年来新发现的从肥胖糖尿病大鼠内脏脂肪组织中分离出的脂肪因子。vaspin与肥胖,IR密切相关,大量研究表明vaspin具有改善胰岛素敏感性作用,同时可以改善糖耐量,调节糖,脂代谢。进一步深入研究vaspin作用机制,可为今后T2DM的诊治提供新的思路。

  【关键词】 vaspin;脂肪因子;肥胖;糖尿病,2型

  Progress in researches on the relationship of vaspin with obese and type 2 diabetes HUANG Shi-peng, LIU Jianying.

  【Summary】 Visceral adipose tissue-derived serine protease inhibitor (vaspin) is a newly discovered adipokine that have been isolated from the visceral fat tissue of obese diabetic rats. Vaspin is closely related with obesity and insulin resistance. Large amount of studies showed that vaspin could increase the insulin sensitivity, improve the glucose tolerance, and regulate the glucose and lipid metabolism. The further and deep researches on vaspin mechanism would provide a new method of diagnosis and treatment for type 2 diabetes.

  【Key words】 Vaspin; Adipokine; Obese; Diabetes mellitus, type 2

上一篇:糖尿病足溃疡感染病原菌特点及药敏分析 下一篇:最终结果:Ghrelin可抑制人体胰岛素分泌,这是其临床意义吗?